Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab Lorenz Kocheise; Jan Kempski; Yunhe Tang; Lorenz Balcar; Victoria Berger; Miriam Tomczak; Joao Gorgulho; Ramsha Masood; Franziska Giehren; Constantin Schmidt; Jan P. Sutter; Thorben W. Fruendt; Francesca Pagani; Sophie Wulf; Julian Kött; Saskia Domanig; Anastasios Giannou; Tanja Bedke; Jöran Lücke; Tao Zhang; Siwen Zhang; Andres Machicote; Ansgar W. Lohse; Marianna Alunni-Fabbroni; Jens Ricke; Najib Ben Khaled; Matthias Pinter; Bernhard Scheiner; Samuel Huber; Johann von Felden; Ignazio Piseddu; Kornelius Schulze;

A landscape of liver cirrhosis and transplantation in Mexico: Changing leading causes and transplant as response Icela Palma-Lara; María Guadalupe Ortiz-López; José Bonilla-Delgado; Juanita Pérez-Escobar; Ricardo Godínez-Aguilar; Claudia Luévano-Contreras; Ana María Espinosa-García; Javier Pérez-Durán; Patricia García Alonso-Themann; Manuel Nolasco-Quiroga; Javier Flores-Estrada; Paulina Carpinteyro-Espin; Daniel Juárez-Ascencio; Nayeli Goreti Nieto-Velazquez; Carmen Palacios-Reyes;

Integrated analyses and a novel nomogram for the prediction of significant fibrosis in patients Mengxin Lu; Shuai Tao; Xinyan Li; Qunling Yang; Cong Du; Weijia Lin; Shuangshuang Sun; Conglin Zhao; Neng Wang; Qiankun Hu; Yuxian Huang; Qiang Li; Yi Zhang; Liang Chen;